Observational studyThe British journal of ophthalmology2024
Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).
Observational study in The British journal of ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Orbital MRI for thyroid eye disease activity staging: a systematic review and meta-analysis.BMC ophthalmology · 2026Pooled it
- Association between serum immunoglobulin G4 levels and Graves' ophthalmopathy: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Quality of life and psychosocial well-being in thyroid eye disease in Japan: pre-teprotumumab national survey.Journal of the Endocrine Society · 2026Article
- Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression.The Journal of clinical endocrinology and metabolism · 2026Observational
- Diagnosis and treatment progress of upper eyelid abnormalities in thyroid-eye disease.Frontiers in endocrinology · 2026Review
- Dynamic Monitoring of Thyroid-Stimulating Hormone Receptor Antibody and Extraocular Muscle Thickness: A Clinical Risk Stratification Model for Recurrence Risk Post-Glucocorticoid Therapy in TED Patients.International journal of general medicine · 2026Article
- Clinical value of dual-energy CT parameters combined with morphological features in predicting graves' ophthalmopathy.BMC medical imaging · 2025Article
- Integrative transcriptomic profiling and machine learning reveal hypoxia-associated molecular signatures for precision diagnosis in thyroid eye disease.Human genomics · 2025Article
- Optimal timing for cataract surgery in patients with thyroid-associated ophthalmopathy.International journal of ophthalmology · 2025Article
- White matter structural changes in the visual pathway of thyroid-associated ophthalmopathy patients: a free water and multi-shell diffusion imaging study.Frontiers in neurology · 2025Article
- Temporal trends in the clinical presentation of Graves' orbitopathy: a single-center retrospective study.Journal of endocrinological investigation · 2024Article
- How Age Affects Graves' Orbitopathy-A Tertiary Center Study.Journal of clinical medicine · 2024Article
- Determinants of clinical outcome in patients with moderate/severe Graves' orbitopathy undergoing treatment with parenteral glucocorticoids: a retrospective study.Frontiers in endocrinology · 2024Article
- In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features.Journal of endocrinological investigation · 2023Article
- How patients experience thyroid eye disease.Frontiers in endocrinology · 2023Article
- Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 18 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGraves' orbitopathy (GO) is subject to epidemiological and care-related changes. Aim of the survey was to identify trends in presentation of GO to the European Group On Graves' Orbitopathy (EUGOGO) tertiary referral centres and initial management over time.
methodsProspective observational multicentre study. All new referrals with diagnosis of GO within September-December 2019 were included. Clinical and demographic characteristics, referral timelines and initial therapeutic decisions were recorded. Data were compared with a similar EUGOGO survey performed in 2012.
resultsBesides age (mean age: 50.5±13 years vs 47.7±14 years; p 0.007), demographic characteristics of 432 patients studied in 2019 were similar to those in 2012. In 2019, there was a decrease of severe cases (9.8% vs 14.9; p<0.001), but no significant change in proportion of active cases (41.3% vs 36.6%; p 0.217). After first diagnosis of GO, median referral time to an EUGOGO tertiary centre was shorter (2 (0-350) vs 6 (0-552) months; p<0.001) in 2019. At the time of first visit, more patients were already on antithyroid medications (80.2% vs 45.0%; p<0.001) or selenium (22.3% vs 3.0%; p<0.001). In 2019, the initial management plans for GO were similar to 2012, except for lid surgery (2.4% vs 13.9%; p<0.001) and prescription of selenium (28.5% vs 21.0%; p 0.027).
conclusionGO patients are referred to tertiary EUGOGO centres in a less severe stage of the disease than before. We speculate that this might be linked to a broader awareness of the disease and faster and adequate delivered treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.